Linux中Input输入子系统分析

详细分析了linux系统中input输入子系统的实现代码,从input driver层、input core层、event handler层3个方面介绍了input输入子系统的实现框架及接口类型,对主要数据结构struct input dev、struct input handle、struct input handler、struct input event、input register handle和重要函数input allocate device、input register device、input register handle、input register handler以及sys文件接口实现进行详细说明。     

钢铁精炼晶粒细化一步法初探

将自我研发从粉煤灰中分离提取微珠为主的新型钢铁用精炼晶粒细化复合材料，加入熔融钢铁液中，辅以惰性气体或机械搅动使之在数分钟内与钢液迅速反应，取样、铸坯、检测．精炼脱碳效果明显，晶粒细化等级提高，一步法实现了钢铁精炼脱碳、晶粒细化．在国内外尚属首次用此材料与方法试验研究．     

基于瞬态动力分析的装配式板桥铰缝损伤识别

根据铰缝在装配式板桥传递荷载的作用,通过数值计算方法模拟了装配式板桥在铰缝损伤后的瞬态动力学响应,比较分析了不同损伤程度、不同动荷载加载位置下各板跨中加速度幅值,提出利用多次冲击实验下各板加速度幅值比之差值作为铰缝损伤的评定依据的识别方法,并分析了这种方法的可行性.     

板坯电渣重熔炉结晶器报废原因分析及改进措施

着重对舞钢公司40 t板坯电渣重熔炉结晶器的报废原因进行了分析研究,阐述了针对该类型结晶器所制定的维护、修复与报废标准,同时提出了延长结晶器使用寿命和降低结晶器使用成本方面的一些措施和设想展望。     

A hierarchical test methodology for systems on chip

We present a hierarchical test methodology for testing a SOC with heterogeneous cores, including the 1149.1-wrapped, P1500-wrapped, and BIST memory cores. We propose an 1149.1-based hierarchical test manager that also provides P1500 test control signals. This scheme includes a memory BIST interface, providing both serial and parallel access ports for BIST circuits. Our approach offers low area and pin overhead, and high flexibility     

高压直流输电控制保护系统新技术——WIN-TDC

在新一代直流控制保护系统WIN-TDC中,极控、站控和直流保护等核心部分采用了基于64位精简指令集计算机(RISC)、实时操作系统、64位系统总线的工业控制通用平台--SIMATIC-TDC.SIMATIC-TDC的开发环境采用了单一的编程语言,调试软件集成在开发环境中.人机界面采用了通用工控组态软件--WINCC.利用时分复用(TDM)总线技术实现了测量系统的交叉冗余.WIN-TDC已经在澳大利亚的海底电缆直流工程(BASSLINK)中得到了成功的应用.     

Characterization of Inhibitory Capability on Hyperpolarization-Activated Cation Current Caused by Lutein (β,ε-Carotene-3,3′-Diol), a Dietary Xanthophyll Carotenoid

Lutein (β,ε-carotene-3,3′-diol), a xanthophyll carotenoid, is found in high concentrations in the macula of the human retina. It has been recognized to exert potential effectiveness in antioxidative and anti-inflammatory properties. However, whether and how its modifications on varying types of plasmalemmal ionic currents occur in electrically excitable cells remain incompletely answered. The current hypothesis is that lutein produces any direct adjustments on ionic currents (e.g., hyperpolarization-activated cation current, I_h [or funny current, I_f]). In the present study, GH₃-cell exposure to lutein resulted in a time-, state- and concentration-dependent reduction in I_h amplitude with an IC₅₀ value of 4.1 μM. There was a hyperpolarizing shift along the voltage axis in the steady-state activation curve of I_h in the presence of this compound, despite being void of changes in the gating charge of the curve. Under continued exposure to lutein (3 μM), further addition of oxaliplatin (10 μM) or ivabradine (3 μM) could be effective at either reversing or further decreasing lutein-induced suppression of hyperpolarization-evoked I_h, respectively. The voltage-dependent anti-clockwise hysteresis of I_h responding to long-lasting inverted isosceles-triangular ramp concentration-dependently became diminished by adding this compound. However, the addition of 10 μM lutein caused a mild but significant suppression in the amplitude of erg-mediated or A-type K⁺ currents. Under current-clamp potential recordings, the sag potential evoked by long-lasting hyperpolarizing current stimulus was reduced under cell exposure to lutein. Altogether, findings from the current observations enabled us to reflect that during cell exposure to lutein used at pharmacologically achievable concentrations, lutein-perturbed inhibition of I_h would be an ionic mechanism underlying its changes in membrane excitability.     

Effects of PCSK-9 Inhibition by Alirocumab Treatments on Biliary Cirrhotic Rats

Hyperlipidemia and oxidative stress with elevated oxidized low-density lipoprotein (ox-LDL) exacerbate hepatic inflammation and fibrosis. The plasma level of low-density lipoprotein (LDL) is controlled by proprotein convertase subtilisin/kexin 9 (PCSK9). Alirocumab is a monoclonal antibody that decreases LDL via inhibiting PCSK9 function. Apart from lipid-lowering effects, alirocumab exerts anti-inflammation, anti-angiogenesis and anti-oxidant effects. This study aims to investigate the impact of alirocumab treatment on common bile duct ligation (BDL)-induced biliary cirrhotic rats. After a 4-week treatment of alirocumab, the hemodynamic data, blood biochemistry, ox-LDL level, oxidative stress markers, severity of hepatic encephalopathy and abnormal angiogenesis of BDL rats were measured and compared to the control group. BDL rats presented cirrhotic pictures and elevated ammonia, total cholesterol, LDL and ox-LDL levels compared to the control group. Alirocumab decreased plasma levels of total cholesterol, LDL, and oxidative stress markers; however, it did not affect the hemodynamics, liver and renal biochemistry, and the plasma levels of ammonia and ox-LDL. The motor activities, portal-systemic collaterals and mesenteric vascular density were not significantly different between alirocumab-treated and control groups. In addition, it did not affect hepatic inflammation, intrahepatic angiogenesis, liver fibrosis and free cholesterol accumulation in the liver of BDL rats. In conclusion, PCSK9 inhibition by alirocumab treatment ameliorates hyperlipidemia and systemic oxidative stress in biliary cirrhotic rats. However, it does not affect the plasma level of ox-LDL, intrahepatic inflammation and fibrosis. In addition, PCSK9 inhibition has a neutral effect on abnormal angiogenesis and hepatic encephalopathy in biliary cirrhotic rats.